207 related articles for article (PubMed ID: 25415187)
21. [Comparison of clinical efficacy between first-generation and second-generation tyrosine kinase inhibitors based regimen in the treatment of patients with BCR-ABL positive acute lymphoblastic leukemia].
Liu Y; Mi RH; Chen L; Yuan FF; Yin QS; Fu YW; Zhu XH; Liu XJ; Zhang YL; Zhang WL; Wei XD
Zhonghua Xue Ye Xue Za Zhi; 2019 Sep; 40(9):738-743. PubMed ID: 31648474
[No Abstract] [Full Text] [Related]
22. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
[TBL] [Abstract][Full Text] [Related]
23. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
24. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
[TBL] [Abstract][Full Text] [Related]
25. Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors.
Abou Dalle I; Kantarjian HM; Short NJ; Konopleva M; Jain N; Garcia-Manero G; Garris R; Qiao W; Cortes JE; O'Brien S; Kebriaei P; Kadia T; Jabbour E; Ravandi F
Am J Hematol; 2019 Dec; 94(12):1388-1395. PubMed ID: 31595534
[TBL] [Abstract][Full Text] [Related]
26. [Comparison of Clinical Outcomes between P190 and P210 Trans-cripts in Adult Ph Chromosome Positive Acute Lymphoblastic Leukemia in the New Era of TKI].
Qiu LL; Lu YJ; Jing Y; Yu L; Liu DH; Wang LL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):369-74. PubMed ID: 27150994
[TBL] [Abstract][Full Text] [Related]
27. [The relationship between the persistence of the BCR/ABL gene and relapse in adult patients with acute lymphoblastic leukemia].
Anguita E; Villegas A; González FA; del Potro E; Martínez R; Alvarez A; Díaz-Mediavilla J; Ferro MT; Espinós D
Med Clin (Barc); 1999 Apr; 112(13):481-4. PubMed ID: 10353112
[TBL] [Abstract][Full Text] [Related]
28. Detection and significance of bcr-abl mRNA transcripts and fusion proteins in Philadelphia-positive adult acute lymphoblastic leukemia.
Tuszynski A; Dhut S; Young BD; Lister TA; Rohatiner AZ; Amess JA; Chaplin T; Dorey E; Gibbons B
Leukemia; 1993 Oct; 7(10):1504-8. PubMed ID: 8412311
[TBL] [Abstract][Full Text] [Related]
29. [Risk Factors of Leukemia-free Survival in Ph
Bao XB; Cai WZ; He XF; Chen SN; Qiu HY; Sun AN; Wu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1787-1792. PubMed ID: 29262917
[TBL] [Abstract][Full Text] [Related]
30. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
Ottmann OG; Wassmann B; Pfeifer H; Giagounidis A; Stelljes M; Dührsen U; Schmalzing M; Wunderle L; Binckebanck A; Hoelzer D;
Cancer; 2007 May; 109(10):2068-76. PubMed ID: 17429836
[TBL] [Abstract][Full Text] [Related]
31. [Application of imatinib in BCR- ABL positive acute lymphoblastic leukemia treatment in the real world].
Wan YL; Wang Y; Liu BC; Liu X; Gong XY; Zhao XL; Wang TY; Jiang EL; Feng SZ; Han MZ; Qiu LG; Mi YC; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2016 Oct; 37(10):886-891. PubMed ID: 27801322
[TBL] [Abstract][Full Text] [Related]
32. [Second-generation tyrosine kinase inhibitors combined with allogeneic hematopoietic stem cell transplant for Philadelphia chromosome positive leukemia].
Yu X; Li C; Wu X; Ye L; Liu H; Ma C; Ma J; Gu C; Wu D
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):129-33. PubMed ID: 24606654
[TBL] [Abstract][Full Text] [Related]
33. [Clinical study of imatinib for treatment of Philadelphia chromosome positive acute lymphoblastic leukemia.].
Li CX; Wu DP; Liu H; Liu YJ; Ma X; Wu XJ; Chen XC; Sun DP
Zhonghua Xue Ye Xue Za Zhi; 2010 Mar; 31(3):181-5. PubMed ID: 20510109
[TBL] [Abstract][Full Text] [Related]
34. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.
Martinelli G; Iacobucci I; Storlazzi CT; Vignetti M; Paoloni F; Cilloni D; Soverini S; Vitale A; Chiaretti S; Cimino G; Papayannidis C; Paolini S; Elia L; Fazi P; Meloni G; Amadori S; Saglio G; Pane F; Baccarani M; Foà R
J Clin Oncol; 2009 Nov; 27(31):5202-7. PubMed ID: 19770381
[TBL] [Abstract][Full Text] [Related]
35. Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia.
Pane F; Cimino G; Izzo B; Camera A; Vitale A; Quintarelli C; Picardi M; Specchia G; Mancini M; Cuneo A; Mecucci C; Martinelli G; Saglio G; Rotoli B; Mandelli F; Salvatore F; Foà R;
Leukemia; 2005 Apr; 19(4):628-35. PubMed ID: 15744351
[TBL] [Abstract][Full Text] [Related]
36. [Predictive value of molecular response after treatment with tyrosine kinase inhibitor for 3 months in patients with chronic myeloid leukemia].
Geng SX; Weng JY; Huang X; Lu ZS; Wu P; Huang LS; Liu L; Du X
Zhonghua Xue Ye Xue Za Zhi; 2013 Jul; 34(7):561-5. PubMed ID: 23906446
[TBL] [Abstract][Full Text] [Related]
37. Hematopoietic stem cell transplant versus chemotherapy plus tyrosine kinase inhibitor in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL).
Salami K; Alkayed K; Halalsheh H; Hussein AA; Riziq M; Madanat F
Hematol Oncol Stem Cell Ther; 2013 Mar; 6(1):34-41. PubMed ID: 23664604
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of a normal karyotype in adult patients with BCR-ABL1-positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era.
Shi T; Wang H; Xie M; Li X; Zhu L; Ye X
Clinics (Sao Paulo); 2020; 75():e2011. PubMed ID: 33206758
[TBL] [Abstract][Full Text] [Related]
39. Additional chromosomal abnormalities and variability of BCR breakpoints in Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia in Taiwan.
Ko BS; Tang JL; Lee FY; Liu MC; Tsai W; Chen YC; Wang CH; Sheng MC; Lin DT; Lin KH; Tien HF
Am J Hematol; 2002 Dec; 71(4):291-9. PubMed ID: 12447959
[TBL] [Abstract][Full Text] [Related]
40. Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92.
Schlieben S; Borkhardt A; Reinisch I; Ritterbach J; Janssen JW; Ratei R; Schrappe M; Repp R; Zimmermann M; Kabisch H; Janka-Schaub G; Bartram CR; Ludwig WD; Riehm H; Lampert F; Harbott J
Leukemia; 1996 Jun; 10(6):957-63. PubMed ID: 8667652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]